<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47360/1995-4484-2024-280-285</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-3575</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Факторы, влияющие на частоту приступов артрита, у пациентов с подагрой, не получающих уратснижающую терапию (результаты пилотного ретроспективного исследования)</article-title><trans-title-group xml:lang="en"><trans-title>Factors affecting the frequency of arthritis attacks in patients with gout not receiving urate-lowering therapy (results of a pilot retrospective study)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1191-5831</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Елисеев</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Eliseev</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елисеев Максим Сергеевич</p><p>115522, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>Maxim S. Eliseev</p><p>115522, Moscow, Kashirskoye Highway, 34A</p></bio><email xlink:type="simple">elicmax@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5394-7869</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Желябина</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zheliabina</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>Olga V. Zheliabina</p><p>115522, Moscow, Kashirskoye Highway, 34A</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4383-9872</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Панина</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Panina</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>Elena V. Panina</p><p>115522, Moscow, Kashirskoye Highway, 34A</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»<country>Россия</country></aff><aff xml:lang="en">V.A. Nasonova Research Institute of Rheumatology<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>26</day><month>06</month><year>2024</year></pub-date><volume>62</volume><issue>3</issue><fpage>280</fpage><lpage>285</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Елисеев М.С., Желябина О.В., Панина Е.В., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Елисеев М.С., Желябина О.В., Панина Е.В.</copyright-holder><copyright-holder xml:lang="en">Eliseev M.S., Zheliabina O.V., Panina E.V.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/3575">https://rsp.mediar-press.net/rsp/article/view/3575</self-uri><abstract><p>Подагра проявляется острыми приступами артрита, частота которых варьирует и непредсказуема.</p><p>Цель работы – выявление факторов, связанных с частотой приступов артрита, у пациентов с подагрой, не получавших уратснижающую терапию (УСТ).</p><sec><title>Материалы и методы</title><p>Материалы и методы. В ретроспективное когортное исследование были включены 116 пациентов (6 женщин, 110 мужчин) с подагрой, не получавшие УСТ; средний возраст 50,10±12,05 года. Оценивались частота приступов артрита за последний год и наличие подкожных тофусов. Анализируемые факторы включали: факт употребления алкоголя; курение; индекс массы тела (ИМТ); артериальное давление (АД); наличие  сопутствующих заболеваний; прием диуретиков. При лабораторном исследовании определялись уровни глюкозы, креатинина, креатинфосфокиназы (КФК), γ-глютамилтранспептидазы (ГГТП), щелочной фосфатазы (ЩФ), мочевой кислоты (МК), С-реактивного белка (СРБ), рассчитывалась скорость клубочковой фильтрации (СКФ).</p></sec><sec><title>Результаты</title><p>Результаты. Медиана длительности заболевания составила 9,2 [3,9; 15,8] года, числа приступов артрита в год – 5 [2; 6]; у 40% больных отмечалось ≥4 приступов артрита в год, у 33,6% – подкожные тофусы. Была выявлена слабая положительная корреляционная связь частоты обострений со значением диастолического АД (ДАД; р&lt;0,001), уровнем ГГТП (р&lt;0,001), КФК (р=0,120) и СРБ сыворотки (р=0,040). Сывороточный уровень МК коррелировал только с количеством подкожных тофусов (p=0,017), но не с частотой приступов артрита (р=0,972). Отмечалась статистически значимая ассоциация числа пациентов, имевших ≥4 приступов артрита, с наличием семейного анамнеза подагры (отношение шансов (ОШ) – 1,955; 95%-й доверительный интервал (95% ДИ): 1,224–3,121; p&lt;0,05), тофусов (ОШ=1,746; 95% ДИ: 1,161–2,626; p=0,007), употреблением алкоголя (ОШ=2,656; 95% ДИ: 1,766–3,994; p&lt;0,001), уровнем МК ≥540 мкмоль/л (ОШ=1,586; 95% ДИ: 1,041–2,416; р=0,031). У принимающих диуретики приступы развивались чаще (р&lt;0,001).</p></sec><sec><title>Вывод</title><p>Вывод. Частота приступов артрита у пациентов с нелеченной подагрой может быть связана с наличием подкожных тофусов, значением ДАД, сывороточным уровнем ГГТП, МК&gt;540 мкмоль/л, приемом диуретиков и алкоголя.</p></sec></abstract><trans-abstract xml:lang="en"><p>Gout manifests as acute arthritis attacks, the frequency of which varies and is unpredictable.</p><p>The aim of this study was to identify factors associated with the frequency of arthritis attacks in patients with gout who have not received urate-lowering therapy (ULT).</p><sec><title>Materials and methods</title><p>Materials and methods. A retrospective cohort study included 116 patients (6 females, 110 males) with gout, with a mean age of 50.1±12.05 years, who were not receiving ULT. The frequency of arthritis attacks in the past year and the presence of subcutaneous tophi were evaluated. Analyzed factors included alcohol consumption, smoking, body mass index (BMI), blood pressure values, comorbidities, diuretic use, and laboratory tests, including serum levels of glucose, creatinine, creatine phosphokinase (CPK), gamma-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP), uric acid (UA), C-reactive protein (CRP), and estimated glomerular filtration rate (eGFR).</p></sec><sec><title>Results</title><p>Results. The mean disease duration was 9.2 [3.9; 15.8] years. The average number of arthritis attacks per year was 5 [2; 6], with ≥4 arthritis attacks per year observed in 40% of patients, and subcutaneous tophi present in 33.6%. A weak positive correlation was found between the frequency of exacerbations and systolic blood pressure (p&lt;0.001), serum GGT levels (p&lt;0.001), CPK levels (p=0.120), and serum CRP levels (p=0.040). Serum UA levels correlated only with the presence of subcutaneous tophi (p=0.017), but not with the frequency of arthritis attacks (p=0.972). OR &gt;4 attacks of arthritis was significant for: presence of heredity for gout – 1.955 (95% CI: 1.224–3.121; p&lt;0.05); presence of tophi – 1.746 (95% CI: 1.161–2.626; p=0.007); alcohol consumption – 2.656 (95% CI: 1.766–3.994; p&lt;0.001); in the presence of a sUA level ≥540 µmol/l – 1.586 (95% CI: 1.041–2.416; p=0.031). Diuretics users had attacks more frequently (р&lt;0,001).</p></sec><sec><title>Conclusion</title><p>Conclusion. The frequency of arthritis attacks in untreated gout patients may be associated with the presence of subcutaneous tophi, systolic blood pressure values, serum GGT, uric acid levels (when &gt;540 µmol/L), diuretic use, and alcohol consumption.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>обострение</kwd><kwd>подагра</kwd><kwd>мочевая кислота</kwd><kwd>риск обострения</kwd><kwd>факторы риска</kwd><kwd>течение подагры</kwd><kwd>частота обострений</kwd></kwd-group><kwd-group xml:lang="en"><kwd>exacerbation</kwd><kwd>gout</kwd><kwd>uric acid</kwd><kwd>risk of exacerbation</kwd><kwd>risk factors</kwd><kwd>course of gout</kwd><kwd>frequency of exacerbations</kwd></kwd-group><funding-group xml:lang="ru"><funding-statement>Работа выполнена в рамках фундаментальной научной темы «Разработка междисциплинарной персонализированной модели оказания помощи пациентам с аутовоспалительными дегенеративными заболеваниями» (№ 1021051403074-2)</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Abhishek A, Valdes AM, Zhang W, Doherty M. Association of serum uric acid and disease duration with frequent gout attacks: A case-control study. Arthritis Care Res (Hoboken). 2016;68(10):1573-1577. doi: 10.1002/acr.22855</mixed-citation><mixed-citation xml:lang="en">Abhishek A, Valdes AM, Zhang W, Doherty M. Association of serum uric acid and disease duration with frequent gout attacks: A case-control study. Arthritis Care Res (Hoboken). 2016;68(10):1573-1577. doi: 10.1002/acr.22855</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС. Классификационные критерии подагры (рекомендации ACR/EULAR). Научно-практическая ревматология. 2015; 53(6): 581-585. doi: 10.14412/1995-4484-2015-581-585</mixed-citation><mixed-citation xml:lang="en">Eliseev MS. Gout classification criteria (ACR/EULAR guidelines). Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2015;53(6):581-585 (In Russ.). doi: 10.14412/1995-4484-2015-581-585</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Khanna PP, Nuki G, Bardin T, Tausche AK, Forsythe A, Goren A, Vietri J, et al. Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. Health Qual Life Outcomes. 2012;10:117. doi: 10.1186/1477-7525-10-117</mixed-citation><mixed-citation xml:lang="en">Khanna PP, Nuki G, Bardin T, Tausche AK, Forsythe A, Goren A, Vietri J, et al. Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. Health Qual Life Outcomes. 2012;10:117. doi: 10.1186/1477-7525-10-117</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Кузьмина АП, Лазаренко ОН. Показатели качества жизни и функционального статуса больных артериальной гипертензией с коморбидной подагрой. Семейная медицина. 2019;82(2):89-93. doi: 10.30841/2307-5112.2.2019.175658</mixed-citation><mixed-citation xml:lang="en">Kuzmina AP, Lazarenko HE. Indicators of quality of life and functional status of patients with arterial hypertension and gout. Family Medicine. 2019;82(2):89-93 (In Russ.). doi: 10.30841/2307-5112.2.2019.175658</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis. 2008;67(9):1310-1316. doi: 10.1136/ard.2007.081604</mixed-citation><mixed-citation xml:lang="en">Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann Rheum Dis. 2008;67(9):1310-1316. doi: 10.1136/ard.2007.081604</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Dalbeth N, Phipps-Green A, Frampton C, Neogi T, Taylor WJ, Merriman TR. Relationship between serum urate concentration and clinically evident incident gout: An individual participant data analysis. Ann Rheum Dis. 2018;77(7):1048-1052. doi: 10.1136/annrheumdis-2017-212288</mixed-citation><mixed-citation xml:lang="en">Dalbeth N, Phipps-Green A, Frampton C, Neogi T, Taylor WJ, Merriman TR. Relationship between serum urate concentration and clinically evident incident gout: An individual participant data analysis. Ann Rheum Dis. 2018;77(7):1048-1052. doi: 10.1136/annrheumdis-2017-212288</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Neogi T, Chen C, Niu J, Chaisson C, Hunter DJ, Zhang Y. Alcohol quantity and type on risk of recurrent gout attacks: An internet-based case-crossover study. Am J Med. 2014;127(4):311-318. doi: 10.1016/j.amjmed.2013.12.019</mixed-citation><mixed-citation xml:lang="en">Neogi T, Chen C, Niu J, Chaisson C, Hunter DJ, Zhang Y. Alcohol quantity and type on risk of recurrent gout attacks: An internet-based case-crossover study. Am J Med. 2014;127(4):311-318. doi: 10.1016/j.amjmed.2013.12.019</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС, Чикаленкова НА, Барскова ВГ. Клинические особенности подагры у женщин: результаты сравнительного исследования. Научно-практическая ревматология. 2014;52(2):178-182. doi: 10.14412/1995-4484-2014-178-182</mixed-citation><mixed-citation xml:lang="en">Eliseev MS, Chikalenkova NA, Barskova VG. Clinical features of gout in women: The results of a comparative study. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2014;52(2):178-182 (In Russ.). doi: 10.14412/1995-4484-2014-178-182</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев MС, Барскова ВГ. Метаболический синдром при подагре. Вестник Российской академии медицинских наук. 2008;6:29-32.</mixed-citation><mixed-citation xml:lang="en">Eliseev MS, Barskova VG. Metabolic syndrome in gout. Annals of the Russian Academy of Medical Sciences. 2008;6:29-32 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Чикина МН. Профилактика приступов артрита при назначении уратснижающей терапии у больных подагрой. Научнопрактическая ревматология. 2018;56(6);760-766. doi: 10.14412/1995-4484-2018-760-766</mixed-citation><mixed-citation xml:lang="en">Chikina MN. Prevention of arthritis attacks in the use of urate-lowering therapy in patients with gout. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2018;56(6):760-766 (In Russ.). doi: 10.14412/1995-4484-2018-760-766</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 gout classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol. 2015;67(10):2557-2568. doi: 10.1002/art.39254</mixed-citation><mixed-citation xml:lang="en">Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, et al. 2015 gout classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol. 2015;67(10):2557-2568. doi: 10.1002/art.39254</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Gaffo AL, Schumacher HR, Saag KG, Taylor WJ, Dinnella J, Outman R, et al. Developing a provisional definition of flare in patients with established gout. Arthritis Rheum. 2012;64(5):1508- 1517. doi: 10.1002/art.33483</mixed-citation><mixed-citation xml:lang="en">Gaffo AL, Schumacher HR, Saag KG, Taylor WJ, Dinnella J, Outman R, et al. Developing a provisional definition of flare in patients with established gout. Arthritis Rheum. 2012;64(5):1508- 1517. doi: 10.1002/art.33483</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Brill JM, McCarty DJ. Studies on the nature of gouty tophy. Ann Intern Med. 1964;60:486-505. doi: 10.7326/0003-4819-60-3-486</mixed-citation><mixed-citation xml:lang="en">Brill JM, McCarty DJ. Studies on the nature of gouty tophy. Ann Intern Med. 1964;60:486-505. doi: 10.7326/0003-4819-60-3-486</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Bursill D, Taylor WJ, Terkeltaub R, Kuwabara M, Merriman TR, Grainger R, et al. Gout, hyperuricemia, and crystal-associated disease network consensus statement regarding labels and definitions for disease elements in gout. Arthritis Care Res (Hoboken). 2019;71(3):427-434. doi: 10.1002/acr.23607</mixed-citation><mixed-citation xml:lang="en">Bursill D, Taylor WJ, Terkeltaub R, Kuwabara M, Merriman TR, Grainger R, et al. Gout, hyperuricemia, and crystal-associated disease network consensus statement regarding labels and definitions for disease elements in gout. Arthritis Care Res (Hoboken). 2019;71(3):427-434. doi: 10.1002/acr.23607</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3):321-325. doi: 10.1002/art.20405</mixed-citation><mixed-citation xml:lang="en">Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3):321-325. doi: 10.1002/art.20405</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450-2461. doi: 10.1056/NEJMoa050373</mixed-citation><mixed-citation xml:lang="en">Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450-2461. doi: 10.1056/NEJMoa050373</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Urano W, Yamanaka H, Tsutani H, Nakajima H, Matsuda Y, Taniguchi A, et al. The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J Rheumatol. 2002;29(9):1950-1953.</mixed-citation><mixed-citation xml:lang="en">Urano W, Yamanaka H, Tsutani H, Nakajima H, Matsuda Y, Taniguchi A, et al. The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis. J Rheumatol. 2002;29(9):1950-1953.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F, et al. Gout. Nat Rev Dis Primers. 2019;5(1):69. doi: 10.1038/s41572-019-0115-y</mixed-citation><mixed-citation xml:lang="en">Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F, et al. Gout. Nat Rev Dis Primers. 2019;5(1):69. doi: 10.1038/s41572-019-0115-y</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Yoshida K, Glynn RJ, Choi HK, Everett BM, Li Y, MacFadyen JG, et al. Canakinumab’s effect against subsequent gout flares and high-sensitivity C-reactive protein levels: A causal mediation analysis. Arthritis Care Res (Hoboken). 2023;75(4):817-824. doi: 10.1002/acr.24832</mixed-citation><mixed-citation xml:lang="en">Yoshida K, Glynn RJ, Choi HK, Everett BM, Li Y, MacFadyen JG, et al. Canakinumab’s effect against subsequent gout flares and high-sensitivity C-reactive protein levels: A causal mediation analysis. Arthritis Care Res (Hoboken). 2023;75(4):817-824. doi: 10.1002/acr.24832</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Solomon DH, Glynn RJ, MacFadyen JG, Libby P, Thuren T, Everett BM, et al. Relationship of interleukin-1β blockade with incident gout and serum uric acid levels: Exploratory analysis of a randomized controlled trial. Ann Intern Med. 2018;169(8):535- 542. doi: 10.7326/M18-1167</mixed-citation><mixed-citation xml:lang="en">Solomon DH, Glynn RJ, MacFadyen JG, Libby P, Thuren T, Everett BM, et al. Relationship of interleukin-1β blockade with incident gout and serum uric acid levels: Exploratory analysis of a randomized controlled trial. Ann Intern Med. 2018;169(8):535- 542. doi: 10.7326/M18-1167</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Liu W, Song H, Man S, Li H, Gao S. Simple metabolic markers associated with tophaceous gout. Clin Rheumatol. 2021;40(12):5047-5053. doi: 10.1007/s10067-021-05861-x</mixed-citation><mixed-citation xml:lang="en">Liu W, Song H, Man S, Li H, Gao S. Simple metabolic markers associated with tophaceous gout. Clin Rheumatol. 2021;40(12):5047-5053. doi: 10.1007/s10067-021-05861-x</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Corti A, Belcastro E, Dominici S, Maellaro E, Pompella A. The dark side of gamma-glutamyltransferase (GGT): Pathogenic effects of an ‘antioxidant’ enzyme. Free Radic Biol Med. 2020;160:807-819. doi: 10.1016/j.freeradbiomed.2020.09.005</mixed-citation><mixed-citation xml:lang="en">Corti A, Belcastro E, Dominici S, Maellaro E, Pompella A. The dark side of gamma-glutamyltransferase (GGT): Pathogenic effects of an ‘antioxidant’ enzyme. Free Radic Biol Med. 2020;160:807-819. doi: 10.1016/j.freeradbiomed.2020.09.005</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Громова МА, Цурко ВВ, Кисляк ОА, Дворников АС. Биохимические показатели крови у пациентов с подагрой и бессимптомной гиперурикемией: предикторы артрита. Лечебное дело. 2022;3-4:64-70. doi: 10.24412/2071-5315-2022-12919</mixed-citation><mixed-citation xml:lang="en">Gromova MA, Tsurko VV, Kislyak OA, Dvornikov AS. Biochemical parameters in blood of patients with gout and asymptomatic hyperuricemia: Predictors of arthritis. Lechebnoe delo. 2022;3-4:64-70 (In Russ.). doi: 10.24412/2071-5315-2022-12919</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: Executive summary. Rheumatology (Oxford). 2020;59(3):487-494. doi: 10.1093/rheumatology/kez664</mixed-citation><mixed-citation xml:lang="en">Mackie SL, Dejaco C, Appenzeller S, Camellino D, Duftner C, Gonzalez-Chiappe S, et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: Executive summary. Rheumatology (Oxford). 2020;59(3):487-494. doi: 10.1093/rheumatology/kez664</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Chen X, You J, Zhou M, Ma H, Huang C. The association between serum uric acid and creatine phosphokinase in the general population: NHANES 2015–2018. BMC Cardiovasc Disord. 2023;23(1):296. doi: 10.1186/s12872-023-03333-5</mixed-citation><mixed-citation xml:lang="en">Chen X, You J, Zhou M, Ma H, Huang C. The association between serum uric acid and creatine phosphokinase in the general population: NHANES 2015–2018. BMC Cardiovasc Disord. 2023;23(1):296. doi: 10.1186/s12872-023-03333-5</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Барскова ВГ, Елисеев МС, Насонова ВА, Насонов Е.Л. Алкоголь и клиническая картина у больных подагрой. Современная ревматология. 2007;1:37-42.</mixed-citation><mixed-citation xml:lang="en">Barskova VG, Eliseev MS, Nasonova VA, Nasonov EL. Alcohol and the clinical picture of gout. Modern Rheumatology Journal. 2007;1:37-42 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Chen SY, Chen CL, Shen ML, Kamatani N. Trends in the manifestations of gout in Taiwan. Rheumatology (Oxford). 2003;42(12):1529-1533. doi: 10.1093/rheumatology/keg422</mixed-citation><mixed-citation xml:lang="en">Chen SY, Chen CL, Shen ML, Kamatani N. Trends in the manifestations of gout in Taiwan. Rheumatology (Oxford). 2003;42(12):1529-1533. doi: 10.1093/rheumatology/keg422</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС. Рекомендации Американской коллегии ревматологов (2020 г.) по ведению больных подагрой: что нового и что спорно. Научно-практическая ревматология. 2021;59(2):129-133. doi: 10.47360/1995-4484-2021-129-133</mixed-citation><mixed-citation xml:lang="en">Eliseev MS. ACR management guidelines for the treatment of gout: What’s new and what’s controversial. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2021;59(2):129-133 (In Russ.). doi: 10.47360/1995-4484-2021-129-133</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Nieradko-Iwanicka B. The role of alcohol consumption in pathogenesis of gout. Crit Rev Food Sci Nutr. 2022;62(25):7129-7137. doi: 10.1080/10408398.2021.1911928</mixed-citation><mixed-citation xml:lang="en">Nieradko-Iwanicka B. The role of alcohol consumption in pathogenesis of gout. Crit Rev Food Sci Nutr. 2022;62(25):7129-7137. doi: 10.1080/10408398.2021.1911928</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Елисеев МС, Желябина ОВ, Черемушкина ЕВ. Сравнение частоты и количества употребления в пищу мясных продуктов у пациентов с подагрой и асимптоматической гиперурикемией (предварительные данные пилотного исследования). РМЖ. Медицинское обозрение. 2023;7(7):445-451. doi: 10.32364/2587-6821-2023-7-7-7</mixed-citation><mixed-citation xml:lang="en">Eliseev MS, Zhelyabina OV, Cheremushkina EV. Frequency and quantity comparison of meat and fish products consumption in patients with gout and asymptomatic hyperuricemia (preliminary data of the pilot study). Russian Medical Inquiry. 2023;7(7):445-451 (In Russ.). doi: 10.32364/2587-6821-2023-7-7-7</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Dalbeth N, House ME, Horne A, Taylor WJ. Reduced creatinine clearance is associated with early development of subcutaneous tophi in people with gout. BMC Musculoskelet Disord. 2013;14:363. doi: 10.1186/1471-2474-14-363</mixed-citation><mixed-citation xml:lang="en">Dalbeth N, House ME, Horne A, Taylor WJ. Reduced creatinine clearance is associated with early development of subcutaneous tophi in people with gout. BMC Musculoskelet Disord. 2013;14:363. doi: 10.1186/1471-2474-14-363</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
